StrokeNCT06999122
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
An observational study of Stroke and Hemorrhagic Stroke, run by EMVision Medical Devices Ltd at 8 sites in 2 countries.
Trial summary
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic… Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Stroke, Hemorrhagic Stroke
- What is being tested?
- Brain Scan
- How many people
- 300 participants
- Where
- 8 sitesin 2 countries
- Study dates
- 26 Mar 2025to 28 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 300 subjects across two study arms
Who may be able to join
- Adults ≥22 years of age
- Observable acute neurological deficit suspected to be stroke and within 24 hours of symptom onset
- The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient
- CT or MRI brain imaging following clinical evaluation per standard of care
- Head size deemed suitable for scanning with the EMVision emu™ Brain Scanner -
Who cannot join
- Has received treatment for current (suspected) stroke event prior to initial CT/MRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)
- In-patient for a neurological condition prior to suspected stroke onset
- In-patient in intensive care unit prior to suspected stroke onset
- Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography
- Presence of any implanted electro-stimulating devices in the head and neck
- Presence of any metallic implants in the cranial vault or surrounding bones/tissue (Note that metallic objects distant from the scan area, such as dental implants, nasal piercing etc., are acceptable)
Show all 11Show fewer
- Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device
- Inability to wear the investigational device (skin lesions on scalp, obvious recent blunt or penetrating injury to head, previous intracranial surgeries, neck injury etc.)
- Unable to lie still for the duration of the scan
- Pregnant or breastfeeding
- Any other condition or symptoms preventing the participant from entering the study, according to the investigator´s judgment -
Trial locations and contacts
8 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
8 sites in 2 countries
United States6 sites, 6 recruiting
- Recruiting
Memorial Hermann Memorial City Medical Center
Houston, Texas, 77024
Glenda Torres, 713-500-6153, Glenda.L.Torres@uth.tmc.edu
Aaron M Gusdon, PhD
- Recruiting
UTHealth
Houston, Texas, 77030
Glenda Torres, 713-500-6153, Glenda.L.Torres@uth.tmc.edu
Aaron Gusdon, PhD
- Recruiting
Mayo Jacksonville
Jacksonville, Florida, 32224
Ewa Szymkiewicz, 904-953-3219, Szymkiewicz.Ewa@mayo.edu
William Freeman, PhD
- Recruiting
UCLA
Los Angeles, California, 90095
Sucheta Waghmare, 310-206-5501, SWaghmare@mednet.ucla.edu
May Nour, MD, PHD
- Recruiting
Mount Sinai West
New York, New York, 10019
Megha Dhillon, 212-241-3400, Megha.Dhillon@mountsinai.org
Hazem Shoirah, MD
- Recruiting
Mount Sinai Health System
New York, New York, 10029
Megha Dhillon, 212-241-3400, Megha.Dhillon@mountsinai.org
Hazem Shoirah, MD
Australia2 sites, 2 recruiting
- Recruiting
Liverpool Hospital
Liverpool, New South Wales, 2170
Jasmeen Khan, 0428 292 184, Jasmeen.Khan@health.nsw.gov.au
Dennis Cordato, PhD
- Recruiting
Royal Melbourne Hospital
Parkville, Victoria, 3050
Christine Shin, 03 9342 4413, SooJeong.Shin@mh.org.au
Angela Dos Santos, MD
About this study
Official title: Multi-Center, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.
EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.
Read the detailed description
This clinical investigation is a paired diagnosis, diagnostic performance study intended to quantify the accuracy of the emu™ Brain Scanner's diagnostic output in comparison to current gold-standard practices including multi-modal neuroimaging by CT and/or MRI.
Any adult with neurological deficit suspected to be stroke shall be considered as potentially eligible for the study. Potential participant's eligibility for the study is determined via screening evaluation which includes a review of available demographic and medical history information against the study's inclusion and exclusion criteria, as well as a head size assessment using provided gauges to confirm that their head would fit within the emu™ Brain Scanner. If the screening evaluation finds that the participant is eligible for the study then the investigator proceeds with the informed consent process. This activity occurs in parallel with the investigational site's standard practices for stroke patient management, ensuring no delay in these patients' care.
Regardless of study participation, participants will receive the complete standard of care diagnostic workflow in accordance with applicable national and international guidelines, as well as practices established at the investigational site. The standard of care diagnostic workflow is centered around acute baseline multi-modal CT imaging (and in some instances MRI). Directly following or before this imaging, and without delaying subsequent treatment, a scan is completed with the emu™ Brain Scanner to allow timely coordination between the investigational emu™ Brain Scan result and the reference standard CT/MRI imaging. If the attending physician perceives any potential risk of delaying treatment of the patient then that patient is strictly exclude from the study, entirely at the attending physician's discretion.
A central adjudicating ground truth diagnosis panel is formed of experts in the area of stroke diagnosis and reviews all diagnostic information gathered by the investigational site as per the site's standard of care diagnostic workflow. The ground truth diagnosis panel is blinded to the output from the emu™ Brain Scanner and defines the 'ground truth' or 'reference standard' diagnosis for each patient to ensure accuracy and consistency. Integral to the ground truth diagnosis panel's consideration is the assessment by the core imaging lab, who similarly review all imaging provided by the investigational sites to ensure consistent input to the ground truth expert panel.
The result of the emu™ Brain Scan is compared to the ground truth diagnosis by a biostatistician to determine the accuracy of the emu™ Brain Scanner's diagnostic output (in terms of sensitivity and specificity) with the first output evaluated being intracranial haemorrhage detection in suspected stroke patients. The biostatistician then performs all statistical analyses against the study objectives in accordance with the Statistical Analysis Plan.
- Conditions
- Stroke, Hemorrhagic Stroke
- Being tested
- Brain Scan
- Medical subject headings
- Stroke, Hemorrhagic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Brain ScanDiagnostic test
The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head.
The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues.
| Study group | Role | What they receive |
|---|---|---|
| Intracranial Haemorrhage Group A | Not described Receives: Diagnostic Test: Brain Scan | |
| Other Group B | Group B includes all patients enrolled in the study ultimately diagnosed with a condition other than intracranial haemorrhage, including ischaemic stroke, transient ischaemic attack, or any of a variety of stroke mimicking conditions. Receives: Diagnostic Test: Brain Scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Demonstrate haemorrhage detection sensitivity >80% and specificity >80%
Measured: <30 minutes from acute baseline CT/MRI
Secondary outcomes (4)
Demonstrate the time to complete an emu™ Brain Scan is <15 minutes
Measured: <30 minutes from acute baseline CT/MRI
Evaluate safety of the device
Measured: <30 minutes from acute baseline CT/MRI
Evaluate usability of the device
Measured: <30 minutes from acute baseline CT/MRI
Evaluate device deficiencies
Measured: <30 minutes from acute baseline CT/MRI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2025
- Study start26 Mar 2025
- Primary completion1 Nov 2026 (estimated)
- Study completion28 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- EMVision Medical Devices Ltd
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Reade De Leacy, MBBS(Hons) FRANZCR, Principal investigator, Associate Professor of Neurosurgery and Radiology Director of Neurointerventional Spine Site Director Cerebrovascular Services Mount Sinai Queens Co-director Neuroendovascular Surgery Fellowship Department of Neurosurgery Mount Sinai Health SystemAngela Dos Santos, PhD, Principal investigator, Melbourne Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06999122
- Sponsor's protocol ID
- EMV-CIP-03
- Status last verified
- Jul 2026
- First submitted
- 13 May 2025
- Last updated
- 27 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Center, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
- ClinicalTrials.gov ID
- NCT06999122
- Acronym / sponsor ID
- EMV-CIP-03
- Conditions
- Stroke, Hemorrhagic Stroke
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- EMVision Medical Devices LtdResearch network
- Study start
- 26 Mar 2025 (actual)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 28 Nov 2026 (estimated)
- First posted
- 31 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.
EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.
Detailed description
This clinical investigation is a paired diagnosis, diagnostic performance study intended to quantify the accuracy of the emu™ Brain Scanner's diagnostic output in comparison to current gold-standard practices including multi-modal neuroimaging by CT and/or MRI.
Any adult with neurological deficit suspected to be stroke shall be considered as potentially eligible for the study. Potential participant's eligibility for the study is determined via screening evaluation which includes a review of available demographic and medical history information against the study's inclusion and exclusion criteria, as well as a head size assessment using provided gauges to confirm that their head would fit within the emu™ Brain Scanner. If the screening evaluation finds that the participant is eligible for the study then the investigator proceeds with the informed consent process. This activity occurs in parallel with the investigational site's standard practices for stroke patient management, ensuring no delay in these patients' care.
Regardless of study participation, participants will receive the complete standard of care diagnostic workflow in accordance with applicable national and international guidelines, as well as practices established at the investigational site. The standard of care diagnostic workflow is centered around acute baseline multi-modal CT imaging (and in some instances MRI). Directly following or before this imaging, and without delaying subsequent treatment, a scan is completed with the emu™ Brain Scanner to allow timely coordination between the investigational emu™ Brain Scan result and the reference standard CT/MRI imaging. If the attending physician perceives any potential risk of delaying treatment of the patient then that patient is strictly exclude from the study, entirely at the attending physician's discretion.
A central adjudicating ground truth diagnosis panel is formed of experts in the area of stroke diagnosis and reviews all diagnostic information gathered by the investigational site as per the site's standard of care diagnostic workflow. The ground truth diagnosis panel is blinded to the output from the emu™ Brain Scanner and defines the 'ground truth' or 'reference standard' diagnosis for each patient to ensure accuracy and consistency. Integral to the ground truth diagnosis panel's consideration is the assessment by the core imaging lab, who similarly review all imaging provided by the investigational sites to ensure consistent input to the ground truth expert panel.
The result of the emu™ Brain Scan is compared to the ground truth diagnosis by a biostatistician to determine the accuracy of the emu™ Brain Scanner's diagnostic output (in terms of sensitivity and specificity) with the first output evaluated being intracranial haemorrhage detection in suspected stroke patients. The biostatistician then performs all statistical analyses against the study objectives in accordance with the Statistical Analysis Plan.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intracranial Haemorrhage Group A | – | Diagnostic Test: Brain Scan |
| Other Group B | – | Diagnostic Test: Brain ScanGroup B includes all patients enrolled in the study ultimately diagnosed with a condition other than intracranial haemorrhage, including ischaemic stroke, transient ischaemic attack, or any of a variety of stroke mimicking conditions. |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 300 subjects across two study arms
Key inclusion criteria (5 listed)
- Adults ≥22 years of age
- Observable acute neurological deficit suspected to be stroke and within 24 hours of symptom onset
- The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient
- CT or MRI brain imaging following clinical evaluation per standard of care
- Head size deemed suitable for scanning with the EMVision emu™ Brain Scanner -
Key exclusion criteria (11 listed)
- Has received treatment for current (suspected) stroke event prior to initial CT/MRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)
- In-patient for a neurological condition prior to suspected stroke onset
- In-patient in intensive care unit prior to suspected stroke onset
- Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography
- Presence of any implanted electro-stimulating devices in the head and neck
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Brain ScanThe EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head. The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues. | Diagnostic test | Intracranial Haemorrhage Group A, Other Group B |
Primary outcome
Demonstrate haemorrhage detection sensitivity >80% and specificity >80%
Time frame: <30 minutes from acute baseline CT/MRI
4 secondary outcomes
Demonstrate the time to complete an emu™ Brain Scan is <15 minutes
Time frame: <30 minutes from acute baseline CT/MRI
Evaluate safety of the device
Time frame: <30 minutes from acute baseline CT/MRI
Evaluate usability of the device
Time frame: <30 minutes from acute baseline CT/MRI
Evaluate device deficiencies
Time frame: <30 minutes from acute baseline CT/MRI
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
RecruitingPhase 4
Xeomin® and Gait Related Mobility After Stroke
Stroke
RecruitingObservational study
Implementing Transcranial Direct Current Stimulation in a Rehabilitation Setting
Aphasia, Stroke
Not yet recruiting
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
Ischemic Stroke, Post-stroke Dysphagia
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Reade De Leacy, MBBS(Hons) FRANZCR principal investigator
Associate Professor of Neurosurgery and Radiology Director of Neurointerventional Spine Site Director Cerebrovascular Services Mount Sinai Queens Co-director Neuroendovascular Surgery Fellowship Department of Neurosurgery Mount Sinai Health System
Angela Dos Santos, PhD principal investigator
Melbourne Health
8 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke and Hemorrhagic Stroke, run by EMVision Medical Devices Ltd at 8 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christian Wight, PhD (61 (0) 490 109 797, cwight@emvision.com.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Demonstrate haemorrhage detection sensitivity >80% and specificity >80% (time frame: <30 minutes from acute baseline CT/MRI). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.